Rhode Island Diastolic Dysfunction - Heart Failure
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
To study the hypothesis that treating patients with underlying diastolic dysfunction with
oral Kuvan® (BH4, also known as tetrahydrobiopterin) in addition to current best practices
will improve metabolic and echocardiographic diastolic function parameters.